The U.S. government’s Medicare program on January 11 said it plans to cover Alzheimer’s treatments including Biogen Inc.’s Aduhelm, with some conditions.
Biogen Inc.’s Alzheimer’s drug will be of little help to the company’s third-quarter sales, Wall Street analysts said, as the drugmaker faces an uphill task of convincing hospitals and clinics to use the $56,000-a-year treatment and insurers to reimburse Aduhelm.
President Joe Biden on Aug. 12 called on U.S. lawmakers to enact legislation aimed at lowering drug prices, including allowing Medicare to negotiate drug prices and imposing penalties on drugmakers that hike prices faster than inflation.
Biogen Inc.’s Alzheimer’s drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on July 15 with some large hospitals declining to use Aduhelm and health insurers delaying a decision while awaiting coverage terms from Medicare.
The U.S. government started a review process for national Medicare coverage of Biogen Inc.’s Alzheimer’s drug Aduhelm that was approved during June 2021 by the country’s health regulator.
The Centers for Medicare & Medicaid Services (CMS) announced that ClosedLoop.ai was selected the winner and Geisinger the runner-up in the agency’s Artificial Intelligence Health Outcomes Challenge.
Prescription drug prices dropped 1 percent in 2018 – the first time such a drop has occurred in the United States in 45 years – driven primarily by a greater reliance on generic drugs and much slower increases in branded drugs, according to a government study.
Mallinckrodt Plc received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).
The U.S. Centers for Medicare and Medicaid Services finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc. and Novartis AG.
HHS announced its new price transparency rules for direct-to-consumer TV ads. Now the industry has to sort out what to do about them.
